
MUMBAI — Norwest has closed its largest fund in 65 years, raising $4 billion in fresh global capital as it moves to aggressively ramp up investments across Indian precision manufacturing, industrial services, and healthcare.
Part of the new vehicle, dubbed Norwest 18, will directly fuel expansion in India. The Silicon Valley-headquartered firm already deploys between $250 million and $350 million annually in the country, up from its earlier baselines. With this close, Norwest pushes its total capital under management to $18 billion, spreading growth equity and venture bets across three anchor markets: India, the United States, and Israel.
Capital will chase scale. The firm plans to pursue growth equity, early-stage venture backing, platform plays, and full buyouts.
"Norwest is currently deploying around $250-350 million annually in India, which is higher than the earlier levels of investment," said Niren Shah, managing director and head of Norwest India. "Norwest remains very bullish on India's long-term prospects."
Fintech and consumer-facing startups long dominated venture portfolios in Mumbai and Bengaluru. Norwest is deliberately broadening that horizon. The fund is steering capital into value-added industrial platforms, precision manufacturing, and specialised healthcare providers.
Policy shifts helped force the change. Global equipment makers, wary of concentrated production hubs, now demand diversified supply lines and strict engineering tolerances rather than cheap labor alone. Shah pointed to New Delhi's domestic manufacturing push as a tailwind that is realigning international procurement.
Industrials and Healthcare are becoming increasingly prominent in our investment strategy. Norwest will continue to remain a Multi-strategy fund and focus both on Growth Equity and Venture investments, while also looking to undertake more Platform and Buyout transactions.
Niren Shah, Managing Director and Head of Norwest India
Alongside traditional equity tickets, the firm will deploy venture capital into artificial intelligence and deep-tech platforms, while maintaining active allocations for consumer brands and fintech platforms.
Norwest 18 follows a brisk deployment and liquidity run. Since closing Norwest 17 in April 2024, the investment house backed more than 87 companies and guided upwards of 30 portfolio assets toward initial public offerings and strategic mergers.
Liquidity events stretched across international bourses and enterprise software buyouts:
| Portfolio Company | Transaction Type | Acquirer / Exchange Venue | Sector |
|---|---|---|---|
| Swiggy | Initial Public Offering | Indian Stock Exchanges | Consumer Tech / Quick Commerce |
| Amagi Media Labs | Public Market Listing | Indian Stock Exchanges | Media Technology / Cloud SaaS |
| BillionToOne | Initial Public Offering | US Stock Exchanges | Molecular Diagnostics / Health |
| MBX Biosciences |
Market Context: Global institutional allocators have increasingly rebalanced emerging-market venture allocations toward profitable, cash-generative industrial businesses. Norwest’s push into precision factories reflects an institutional realization: software margins must now meet real-world industrial output to secure resilient portfolio returns.
Norwest’s India leadership will begin committing capital from the $4 billion pool immediately, structuring both growth rounds and buyout acquisitions through the ongoing financial year.
| Initial Public Offering |
| US Stock Exchanges |
| Biotechnology / Therapeutics |
| Omada Health | Initial Public Offering | US Stock Exchanges | Digital Health / Virtual Care |
| Qualified | Strategic Acquisition | Salesforce | Enterprise Software / Conversational Sales |
| Veza | Strategic Acquisition | ServiceNow | Data Security / Identity Governance |
| Ouro Medicines | Strategic Acquisition | Gilead Sciences | Biopharmaceuticals |